kr606.50
0.41% day before yesterday
Stockholm, Dec 23, 05:30 pm CET
ISIN
SE0007692850
Symbol
CAMX

Camurus Stock price

kr606.50
+0.50 0.08% 1M
+13.00 2.19% 6M
+41.00 7.25% YTD
+39.50 6.97% 1Y
+347.50 134.17% 3Y
+419.10 223.64% 5Y
+534.50 742.36% 10Y
+540.50 818.94% 20Y
Stockholm, Closing price Tue, Dec 23 2025
-2.50 0.41%
ISIN
SE0007692850
Symbol
CAMX
Industry

New AI Insights on Camurus Insights AI Insights on Camurus

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
kr36.3b
Enterprise Value
kr32.9b
Net debt
positive
Cash
kr3.5b
Shares outstanding
59.9m
Valuation (TTM | estimate)
P/E
46.8 | 42.7
P/S
15.4 | 14.4
EV/Sales
14.0 | 13.1
EV/FCF
54.3
P/B
8.8
Financial Health
Equity Ratio
87.6%
Return on Equity
13.0%
ROCE
22.0%
ROIC
77.4%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
kr2.4b | kr2.5b
EBITDA
kr949.1m | kr1.0b
EBIT
kr927.2m | kr1.0b
Net Income
kr781.7m | kr850.0m
Free Cash Flow
kr606.0m
Growth (TTM | estimate)
Revenue
39.4% | 34.6%
EBITDA
227.8% | 112.2%
EBIT
237.7% | 112.3%
Net Income
193.6% | 98.4%
Free Cash Flow
100.1%
Margin (TTM | estimate)
Gross
93.5%
EBITDA
40.3% | 41.1%
EBIT
39.4%
Net
33.2% | 33.8%
Free Cash Flow
25.7%
More
EPS
kr13.0
FCF per Share
kr10.1
Short interest
-
Employees
256
Rev per Employee
kr7.3m
Show more

Is Camurus a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Camurus Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Camurus forecast:

13x Buy
87%
2x Hold
13%

Analyst Opinions

15 Analysts have issued a Camurus forecast:

Buy
87%
Hold
13%

Financial data from Camurus

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
2,354 2,354
39% 39%
100%
- Direct Costs 153 153
19% 19%
7%
2,201 2,201
41% 41%
93%
- Selling and Administrative Expenses 705 705
33% 33%
30%
- Research and Development Expense 559 559
25% 25%
24%
949 949
228% 228%
40%
- Depreciation and Amortization 22 22
46% 46%
1%
EBIT (Operating Income) EBIT 927 927
238% 238%
39%
Net Profit 782 782
194% 194%
33%

In millions SEK.

Don't miss a Thing! We will send you all news about Camurus directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Camurus AB operates as a research based pharmaceutical company. The firm engages in the research, development and commercialization of specialty medicines. It provides its products for the treatment of severe and chronic conditions, which includes opioid dependence, pain, cancer and endocrine disorders. The company was founded by Kare Larsson in 1991 and is headquartered in Lund, Sweden.

Head office Sweden
CEO Sven Tiberg
Employees 256
Founded 2004
Website www.camurus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today